S06464 Summary:

BILL NOS06464
 
SAME ASSAME AS A09397
 
SPONSORYOUNG
 
COSPNSROPPENHEIMER, SAVINO
 
MLTSPNSR
 
Add Art 33 SS3301 & 3302, Ins L
 
Regulates step therapy and first fail health insurance policies and contracts.
Go to top    

S06464 Actions:

BILL NOS06464
 
02/13/2012REFERRED TO INSURANCE
Go to top

S06464 Floor Votes:

There are no votes for this bill in this legislative session.
Go to top

S06464 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          6464
 
                    IN SENATE
 
                                    February 13, 2012
                                       ___________
 
        Introduced  by  Sen.  YOUNG  -- read twice and ordered printed, and when
          printed to be committed to the Committee on Insurance
 
        AN ACT to amend the insurance law, in relation to the regulation of step
          therapy and first fail policies
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 

     1    Section  1. The insurance law is amended by adding a new article 33 to
     2  read as follows:
     3                                 ARTICLE 33
     4                       REGULATION OF STEP THERAPY AND
     5                             FIRST FAIL POLICIES
     6  Section 3301. Definitions.
     7          3302. Prescription drug restriction overrides.
     8    § 3301. Definitions. As used in this article:
     9    (a) "Insurer" shall mean any person or entity who offers a  policy  of
    10  accident  and/or health insurance pursuant to section three thousand two
    11  hundred sixteen, three thousand two hundred twenty-one, or four thousand
    12  three hundred three of this chapter or article forty-four of the  public
    13  health law, including managed care providers as defined in section three

    14  hundred sixty-four-j of the social services law;
    15    (b)  "Pharmacy  benefit  management"  or  "PBM" shall mean the service
    16  provided to an insurer, directly or through  another  entity;  including
    17  the  procurement  of  prescription  drugs  to  be  dispensed  to covered
    18  persons, or the administration or management of prescription drug  bene-
    19  fits including, but not limited to, any of the following:
    20    (1) a mail order pharmacy;
    21    (2) claims processing, retail network management and payment of claims
    22  to pharmacies for dispensing prescription drugs;
    23    (3) clinical or other formulary, or preferred drug list development or
    24  management;
    25    (4)  negotiation  or  administration  of  rebates,  discounts, payment

    26  differentials or  other  incentives  for  the  inclusion  of  particular
    27  prescription  drugs  in a particular category or to promote the purchase
    28  of particular prescription drugs;
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD06098-04-2

        S. 6464                             2
 
     1    (5) patient compliance, therapeutic intervention and  generic  substi-
     2  tution programs; and
     3    (6) disease management.
     4    §  3302. Prescription drug restriction overrides. (a) When medications
     5  for the treatment of any medical condition are restricted for use by  an

     6  insurer  or  PBM  by a step therapy or fail first protocol, a prescriber
     7  shall have access to a clear and convenient  process  to  override  such
     8  restrictions  from  the  insurer  and  may  expeditiously  override such
     9  restriction if:
    10    (1) such prescriber, in his or  her  professional  judgment,  believes
    11  that the preferred treatment by the insurer or the PBM has been ineffec-
    12  tive  in the treatment of the covered person's disease or medical condi-
    13  tion; or
    14    (2) based on  sound  clinical  evidence  and  medical  and  scientific
    15  evidence:
    16    (A)  such  prescriber,  in  his or her professional judgment, believes
    17  that the preferred treatment is expected to be ineffective based on  the

    18  known  relevant physical or mental characteristics of the covered person
    19  and known characteristics of the drug regimen, and is likely to be inef-
    20  fective or adversely affect the drug's effectiveness or patient  compli-
    21  ance; or
    22    (B)  such  prescriber,  in  his or her professional judgment, believes
    23  that the preferred treatment has caused or is likely to cause an adverse
    24  reaction or other harm to the covered person.
    25    (b) The duration of any step therapy or fail first protocol shall  not
    26  be longer than either (1) the period deemed necessary by the prescribing
    27  physician or health care professional to determine the treatment's clin-
    28  ical effectiveness, or (2) a period of thirty days.

    29    (c) For medications with no generic equivalent and for which the pres-
    30  criber  in  his  or  her  clinical judgment believes that no appropriate
    31  therapeutic alternative is available, an insurer or  PBM  shall  provide
    32  access to United States Food and Drug Administration (FDA) labeled medi-
    33  cations  without  restriction to treat such medical conditions for which
    34  an FDA labeled medication is available.
    35    (d) Nothing in this section shall require coverage for  an  additional
    36  condition not already covered by the policy or contract, or which is not
    37  otherwise covered by law.
    38    § 2. This act shall take effect on the one hundred twentieth day after
    39  it shall have become a law.
Go to top